Trial Profile
A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler on Lung Function in Subjects With COPD and a Low PIFR
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Revefenacin (Primary) ; Tiotropium bromide
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Mylan; Theravance Biopharma
- 11 Oct 2018 According to a Theravance Biopharma media release, data from this study were presented at the 2018 CHEST annual meeting.
- 11 Oct 2018 Results presented in a Theravance Biopharma media release.
- 08 Oct 2018 According to a Theravance Biopharma media release, data will be presented at at the 2018 CHEST annual meeting.